DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0158968 A1 Panitch Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0158968 A1 Panitch Et Al US 20100158968A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0158968 A1 Panitch et al. (43) Pub. Date: Jun. 24, 2010 (54) CELL-PERMEANT PEPTIDE-BASED Publication Classification INHIBITOR OF KINASES (51) Int. Cl. (76) Inventors: Alyssa Panitch, West Lafayette, IN st e8 CR (US); Brandon Seal, West ( .01) Lafayette, IN (US) A638/10 (2006.01) s A638/16 (2006.01) Correspondence Address: A6IP 43/00 (2006.01) GREENBERG TRAURIG, LLP (52) U.S. Cl. ................ 424/422:514/15: 514/13: 514/14 200 PARKAVE., P.O. BOX 677 FLORHAMPARK, NJ 07932 (US) (57) ABSTRACT The described invention provides kinase inhibiting composi (21) Appl. No.: 12/634,476 tions containing a therapeutic amount of a therapeutic inhibi (22) Filed: Dec. 9, 2009 torpeptide that inhibits at least one kinase enzyme, methods e 19 for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression, and methods Related U.S. Application Data for treating an inflammatory disorder whose pathophysiology (60) Provisional application No. 61/121,396, filed on Dec. comprises inflammatory cytokine expression using the kinase 10, 2008. inhibiting compositions. 20 { ki> | 0: & c s - --- 33- x: SE PEPELE, ics 1.-- E- X K. AAA 22.9 --- KKK. Y.A., 3.2; C. -r { AAEASA. A. E. i : A X AAAAAAA; ; ; ; :-n. 4:-: is SEEKESAN.ARESA, 3523 -- -- Yili.A.R.AKA: 5,342 3. {{RCE: Rix i: Patent Application Publication US 2010/0158968A1 & ******** NO s ***** · Patent Application Publication Jun. 24, 2010 Sheet 2 of 11 US 2010/0158968A1 it, O Peptide: Cso: g E 100 WRRKAWRRKANRO, GWAA. O.737 +I h 90 1AKAFAKAARLYRKALARogvaA FAKAARYRKALARCGWAA, 44301,769 f 80 OYARAAARCARAKALARCLGWAA 22,09 : | KYARAAAROARAKALNROLGVAA 5.842 t E 70 : 5 i 60 if: s i S. t t i 3. 3.w | 30 s: i 10 rower-staxers -ses-toessnesses O.O. (, O OOC Concentration (M) FIGURE 2 Patent Application Publication Jun. 24, 2010 Sheet 3 of 11 US 2010/0158968A1 0.8 - sy KAANROLGWAA KAARCLGWAA 3. A KANAOLGWAA X KANRAGWAA R at KANROAGWAA to KALNR AWAA - KANROLGAAA - No inhibitor Peptide 0.6 O KANRO, GWAA 5 {} g g 0.4 d s s ce l p () 2 t O ex O MK2 inhibitor, M. OO FIGURE 3 Patent Application Publication Jun. 24, 2010 Sheet 4 of 11 US 2010/0158968A1 O. 8 3. () O.2 {x KAd NRO, GWAA KALc NROLGWAA A KANdRO GVAA X KALNRCC, GWAA an KALNROld GWAA -- KANROGWAA -No inhibitor Peptide C KALNROLGWAA 10 MK2 inhibitor, M OO FIGURE 4 Patent Application Publication Jun. 24, 2010 Sheet 5 of 11 US 2010/0158968A1 O5 0.85 - & <- KANROLGVA KKKANRCGWAA x WLRRKAWRRKALNROLGVAA a- -No inhibitor Peptide <> C KANROLGWAA 65 g o in 30.45 c S. (D {} s r t f. 88 O 2 5. S. COs - X 1.g -O.15 ai MK2 inhibitor, uM FIGURE 5 Patent Application Publication Jun. 24, 2010 Sheet 6 of 11 US 2010/0158968A1 ... WRRKA WLRRKAWRRKA, A. YGRKKRRORRR a 0.8 x YARAAAROARA -No inhibitor Peptide KALNROLGWAA S st0.6 - k S. is: s2. d 50.4 k t3 t ". i 0.2 t 0 - kiss. Raw-ex-wee-wxx-x-xxv-wi-worwmem-m-m-mow-mow 1) MK2 inhibitor, M O) FIGURE 6 Patent Application Publication Jun. 24, 2010 Sheet 7 of 11 US 2010/0158968A1 400 C Untreated 1 ng/ml. IL-13 5O i 1 ng/mL L-15 + 0.1 uM Rottlerin 35 is 1 ng/mL L-1B + 1 uM Rottierin i ng/mL L-13 + 100MYARA -X 3 O O is 1 ng/mL L-13 + 300MYARA is 1 ng/mL L-1 3 + 1000MYARA is 1ng/mLIL-1B + 3000MYARA T 2 5O 2OO 150 1OO 5O O Ya-------- rror sw88w88&xtrass | 12hr NS 24h NS -50 - FIGURE 7 Patent Application Publication Jun. 24, 2010 Sheet 8 of 11 US 2010/0158968A1 OUntreated p < 0.05 1 ng/mLTNF-ct 2. 1ng/mLTNF-ct + 0.1M Rotterin is 1ng/ml TNF-c + 1 M Rotterin 2. 1ng/mLTNF-a + 100M FAK is 1ng/mLTNF-a + 300M FAK Rs 1 ng/mLTNF-a + 1000MYARA H 1 ng/mLTNF-a + 3000MYARA W FIGURE 8 Patent Application Publication Jun. 24, 2010 Sheet 9 of 11 US 2010/0158968A1 C. J treated 1Ong/mLTNF-a 1000 - 10mg/mLTNF-ci + 0.1M Rotterin 10mg/mLTMF-a + 1 M Rotterin is 10mg/mLTNF-a + 100 MFAK a 10ngim TNF-a + 300 MFAK 800 is 10ngim TNF-a + 1000MYARA a 10ngiml TNF-a + 3000MYARA 40 2OSO OO 12 NS FIGURE 9 Patent Application Publication Jun. 24, 2010 Sheet 10 of 11 US 2010/0158968A1 zzzzz 838) * 3: Patent Application Publication Jun. 24, 2010 Sheet 11 of 11 US 2010/0158968A1 }} ${}{}}{{########8 US 2010/0158968 A1 Jun. 24, 2010 CELL-PERMEANT PEPTDE-BASED diversity in their Substrate specificity, structure, and the path INHIBITOR OF KINASES ways in which they participate. A recent classification of all available kinase sequences (approximately 60,000 CROSS REFERENCES sequences) indicates kinases can be grouped into 25 families 0001. This application claims the benefit of priority to of homologous proteins. These kinase families are further U.S. provisional application 61/121,396, filed Dec. 10, 2008, assembled into 12 fold groups based on similarity of struc incorporated herein by reference in its entirety. tural fold. Further, 22 of the 25 families (approximately 98.8% of all sequences) belong to 10 fold groups for which STATEMENT OF GOVERNMENT FUNDING the structural fold is known. Of the other 3 families, poly 0002 The described invention was made with government phosphate kinase forms a distinct fold group, and the 2 support under Grant K25HL074968 awarded by the National remaining families are both integral membrane kinases and Institutes of Health. The government has certain rights in the comprise the final fold group. These fold groups not only invention. include some of the most widely spread protein folds, such as Rossmann-like fold (three or more parallel beta strands FIELD OF THE INVENTION linked by two alpha helices in the topological order beta alpha-beta-alpha-beta), ferredoxin-like fold (a common C+B 0003. The described invention relates to cell biology, cell protein fold with a signature off3C.B Secondary structure permeant peptides, cell-permeant peptide compositions, and along its backbone), TIM-barrel fold (meaning a conserved methods of use thereof, and methods of protein engineering. protein fold consisting of eight C-helices and eight parallel B-strands that alternate along the peptide backbone), and BACKGROUND antiparallel B-barrel fold (a beta barrel is a large beta-sheet 0004. The three-dimensional conformation of a protein that twists and coils to form a closed structure in which the molecule is determined by its amino acid sequence, and the first strand is hydrogen bonded to the last), but also all major details of a protein's conformation determine its chemistry. classes (all C, all f, C.--f, C/B) of protein structures. Within a 0005. A protein generally consists of a polypeptide back fold group, the core of the nucleotide-binding domain of each bone with attached side chains. The sequence of the chemi family has the same architecture, and the topology of the cally different side chains of the amino acid makes each protein core is either identical or related by circular permu protein distinct. The folded structure of a protein is stabilized tation. Homology between the families within a fold group is by noncovalent interactions (e.g., hydrogen bonds, ionic not implied. bonds, and van der Waals attractions) that form between different parts of the polypeptide chain. one part of the chain 0009 Group I (23,124 sequences) kinases incorporate and another. The stability of each folded shape is determined protein SITY kinase, atypical protein kinase, lipid kinase, by the combined strength of large numbers of Such noncova and ATP grasp enzymes and further comprise the protein lent bonds. SITY kinase, and atypical protein kinase family (22,074 sequences). These kinases include: choline kinase (EC 2.7.1. 0006 Each protein has four levels of structural organiza 32); protein kinase (EC 2.7.137); phosphorylase kinase (EC tion. The amino acid sequence is the primary structure of the 2.7.1.38); homoserine kinase (EC 2.7.1.39); I-phosphatidyli protein. The secondary structure is defined by patterns of nositol 4-kinase (EC 2.7.1.67); streptomycin 6-kinase (EC hydrogen bonds between backbone amide and carboxyl 2.7.1.72); ethanolamine kinase (EC 2.7.1.82); streptomycin groups without consideration of sidechain-mainchain and 3'-kinase (EC 2.7.1.87); kanamycin kinase (EC 2.7.1.95); sidechain-sidechain hydrogen bond (e.g. C. helix, B-sheet). 5-methylthioribose kinase (EC 2.7.1.100); viomycin kinase The tertiary structure, the full three-dimensional organization (EC 2.7.1.103); hydroxymethylglutaryl-CoA reductase of a polypeptide chain, is the manner in which the sheets and (NADPH) kinase (EC 2.7.1.109); protein-tyrosine kinase helices of the secondary structure of a protein fold on them (EC 2.7.1.112); isocitrate dehydrogenase (NADP+) kinase selves to define the three-dimensional structure. Quaternary (EC 2.7.1.116); myosin light-chain kinase (EC 2.7.1.117): structure refers to the complete structure of a protein mol hygromycin-B kinase (EC 2.7.1.119); calcium/calmodulin ecule formed as a complex of more than one polypeptide dependent protein kinase (EC 2.7.1.123); rhodopsin kinase chain. (EC 2.7.1.125); beta-adrenergic-receptor kinase (EC 2.7.1. 0007 Protein domains are structural units that fold more 126); myosin heavy-chain kinase (EC 2.7.1.129); Tau pro or less independently of each other to form globular compact tein kinase (EC 2.7.1.135); macrollide 2'-kinase (EC 2.7.1.
Load more

Recommended publications
  • DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli
    DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Kath, James Evon. 2016. DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26718716 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA ! ! ! ! ! ! ! DNA!polymerase!exchange!and!lesion!bypass!in!Escherichia)coli! ! A!dissertation!presented! by! James!Evon!Kath! to! The!Committee!on!Higher!Degrees!in!Biophysics! ! in!partial!fulfillment!of!the!requirements! for!the!degree!of! Doctor!of!Philosophy! in!the!subject!of! Biophysics! ! Harvard!University! Cambridge,!Massachusetts! October!2015! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ©!2015!L!James!E.!Kath.!Some!Rights!Reserved.! ! This!work!is!licensed!under!the!Creative!Commons!Attribution!3.0!United!States!License.!To! view!a!copy!of!this!license,!visit:!http://creativecommons.org/licenses/By/3.0/us! ! ! Dissertation!Advisor:!Professor!Joseph!J.!Loparo! ! ! !!!!!!!!James!Evon!Kath! ! DNA$polymerase$exchange$and$lesion$bypass$in$Escherichia)coli$ $ Abstract$ ! Translesion! synthesis! (TLS)! alleviates!
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Rhodopsin Kinase Activity Modulates the Amplitude of the Visual Response in Drosophila
    Rhodopsin kinase activity modulates the amplitude of the visual response in Drosophila Seung-Jae Lee*, Hong Xu, and Craig Montell† Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 Edited by Robert J. Lefkowitz, Duke University Medical Center, Durham, NC, and approved June 30, 2004 (received for review March 29, 2004) A feature shared between Drosophila rhodopsin and nearly all tractability of fly genetics (14). As in mammals, light-activated other G protein-coupled receptors is agonist-dependent protein rhodopsin is phosphorylated and interacts with a protein, arres- phosphorylation. Despite extensive analyses of Drosophila photo- tin, which facilitates deactivation of the receptor. However, transduction, the identity and function of the rhodopsin kinase unlike mammalian phototransduction, light activation in Dro- (RK) have been elusive. Here, we provide evidence that G protein- sophila is coupled to stimulation of phospholipase C rather than coupled receptor kinase 1 (GPRK1), which is most similar to the a cGMP-phosphodiesterase. ␤-adrenergic receptor kinases, G protein-coupled receptor kinase 2 Two Drosophila genes encoding putative GRKs (GPRK1 and (GRK2) and GRK3, is the fly RK. We show that GPRK1 is enriched in GPRK2) were isolated more than a decade ago (15), but were photoreceptor cells, associates with the major Drosophila rhodop- dismissed as candidate RKs due in part to their much greater sin, Rh1, and phosphorylates the receptor. As is the case with similarity to mammalian nonvisual GRKs than to mammalian mammalian GRK2 and GRK3, Drosophila GPRK1 includes a C- RKs. Subsequent analysis of GPRK2 demonstrated that it is terminal pleckstrin homology domain, which binds to phosphoi- expressed in the ovaries and required for egg morphogenesis nositides and the G␤␥ subunit.
    [Show full text]
  • SUPPY Liglucosexlmtdh
    US 20100314248A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0314248 A1 Worden et al. (43) Pub. Date: Dec. 16, 2010 (54) RENEWABLE BOELECTRONIC INTERFACE Publication Classification FOR ELECTROBOCATALYTC REACTOR (51) Int. Cl. (76) Inventors: Robert M. Worden, Holt, MI (US); C25B II/06 (2006.01) Brian L. Hassler, Lake Orion, MI C25B II/2 (2006.01) (US); Lawrence T. Drzal, Okemos, GOIN 27/327 (2006.01) MI (US); Ilsoon Lee, Okemo s, MI BSD L/04 (2006.01) (US) C25B 9/00 (2006.01) (52) U.S. Cl. ............... 204/403.14; 204/290.11; 204/400; Correspondence Address: 204/290.07; 427/458; 204/252: 977/734; PRICE HENEVELD COOPER DEWITT & LIT 977/742 TON, LLP 695 KENMOOR, S.E., PO BOX 2567 (57) ABSTRACT GRAND RAPIDS, MI 495.01 (US) An inexpensive, easily renewable bioelectronic device useful for bioreactors, biosensors, and biofuel cells includes an elec (21) Appl. No.: 12/766,169 trically conductive carbon electrode and a bioelectronic inter face bonded to a surface of the electrically conductive carbon (22) Filed: Apr. 23, 2010 electrode, wherein the bioelectronic interface includes cata lytically active material that is electrostatically bound directly Related U.S. Application Data or indirectly to the electrically conductive carbon electrode to (60) Provisional application No. 61/172,337, filed on Apr. facilitate easy removal upon a change in pH, thereby allowing 24, 2009. easy regeneration of the bioelectronic interface. 7\ POWER 1 - SUPPY|- LIGLUCOSEXLMtDH?till pi 6.0 - esses&aaaas-exx-xx-xx-xx-xxxxixax-e- Patent Application Publication Dec. 16, 2010 Sheet 1 of 18 US 2010/0314248 A1 Potential (nV) Patent Application Publication Dec.
    [Show full text]
  • Balancing the Photoreceptor Proteome: Proteostasis Network Therapeutics for Inherited Retinal Disease
    G C A T T A C G G C A T genes Review Balancing the Photoreceptor Proteome: Proteostasis Network Therapeutics for Inherited Retinal Disease Siebren Faber and Ronald Roepman * Department of Human Genetics and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands * Correspondence: [email protected] Received: 10 June 2019; Accepted: 16 July 2019; Published: 24 July 2019 Abstract: The light sensing outer segments of photoreceptors (PRs) are renewed every ten days due to their high photoactivity, especially of the cones during daytime vision. This demands a tremendous amount of energy, as well as a high turnover of their main biosynthetic compounds, membranes, and proteins. Therefore, a refined proteostasis network (PN), regulating the protein balance, is crucial for PR viability. In many inherited retinal diseases (IRDs) this balance is disrupted leading to protein accumulation in the inner segment and eventually the death of PRs. Various studies have been focusing on therapeutically targeting the different branches of the PR PN to restore the protein balance and ultimately to treat inherited blindness. This review first describes the different branches of the PN in detail. Subsequently, insights are provided on how therapeutic compounds directed against the different PN branches might slow down or even arrest the appalling, progressive blinding conditions. These insights are supported by findings of PN modulators in other research disciplines. Keywords: protein trafficking; protein folding; protein degradation; chaperones; chaperonins; heat shock response; unfolded protein response; autophagy; therapy 1. Introduction The rod and cone photoreceptor (PR) cells are the most abundant cell types in the human retina, with ~6.4 million cones and up to 125 million rods per adult retina [1].
    [Show full text]
  • This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Molecular mechanisms underlying Retinitis pigmentosa type 2 Rodanthi Lyraki Thesis submitted for the degree of Doctor of Philosophy University of Edinburgh 2017 Declaration I declare that this thesis is my own work, and that the experiments described here were conducted by me except where explicitly stated. This work has not been submitted for any other degree or professional qualification. Rodanthi Lyraki, August 2017 ii Preface “Photoreceptors sit on a knife edge separating function and survival from dysfunction and death, and almost any defect seems capable of tipping them towards cell death.” - Alan F. Wright et al., “Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait” iii Acknowledgements I feel very fortunate to have carried out my PhD in the Institute of Genetics and Molecular Medicine in Edinburgh, where I had the opportunity to interact with first- class scientists on a daily basis.
    [Show full text]
  • Abnormal Photoresponses and Light-Induced Apoptosis in Rods Lacking Rhodopsin Kinase
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 3718–3722, March 1999 Cell Biology Abnormal photoresponses and light-induced apoptosis in rods lacking rhodopsin kinase CHING-KANG CHEN*†,MARIE E. BURNS†‡,MARIBETH SPENCER§,GREGORY A. NIEMI§,JEANNIE CHEN¶, i JAMES B. HURLEY§,DENIS A. BAYLOR‡, AND MELVIN I. SIMON* *Division of Biology, 147-75, California Institute of Technology, Pasadena, CA 91125; ‡Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305; §Howard Hughes Medical Institute and Department of Biochemistry, Box 357370, University of Washington, Seattle, WA 98195; and ¶Department of Cell and Neurobiology, University of Southern California, Los Angeles, CA 90033 Contributed by Melvin Simon, January 12, 1999 ABSTRACT Phosphorylation is thought to be an essential 10) and phosphorylate rhodopsin’s C-terminal residues equally first step in the prompt deactivation of photoexcited rhodop- well in vitro (11), it is unclear which kinase is mainly responsible sin. In vitro, the phosphorylation can be catalyzed either by for rhodopsin deactivation in vivo. We determined the role of rhodopsin kinase (RK) or by protein kinase C (PKC). To RK in rhodopsin deactivation in intact rods by deactivating investigate the specific role of RK, we inactivated both alleles both alleles of the RK gene. We found that RK is required for of the RK gene in mice. This eliminated the light-dependent the normal deactivation of rhodopsin and that in its absence, phosphorylation of rhodopsin and caused the single-photon dramatic functional and structural changes occurred. response to become larger and longer lasting than normal. These results demonstrate that RK is required for normal rhodopsin deactivation.
    [Show full text]
  • (12) STANDARD PATENT (11) Application No. AU 2015215937 B2 (19) AUSTRALIAN PATENT OFFICE
    (12) STANDARD PATENT (11) Application No. AU 2015215937 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title Metabolically engineered organisms for the production of added value bio-products (51) International Patent Classification(s) C12N 15/52 (2006.01) C12P 19/26 (2006.01) C12P 19/18 (2006.01) C12P 19/30 (2006.01) (21) Application No: 2015215937 (22) Date of Filing: 2015.08.21 (43) Publication Date: 2015.09.10 (43) Publication Journal Date: 2015.09.10 (44) Accepted Journal Date: 2017.03.16 (62) Divisional of: 2011278315 (71) Applicant(s) Universiteit Gent (72) Inventor(s) MAERTENS, Jo;BEAUPREZ, Joeri;DE MEY, Marjan (74) Agent / Attorney Griffith Hack, GPO Box 3125, Brisbane, QLD, 4001, AU (56) Related Art Trinchera, M. et al., 'Dictyostelium cytosolic fucosyltransferase synthesizes H type 1 trisaccharide in vitro', FEBS Letters, 1996, Vol. 395, pages 68-72 GenBank accession no. AF279134, 6 May 2002 van der Wel, H. et al., 'A bifunctional diglycosyltransferase forms the Fuc#1,2Gal#1,3-disaccharide on Skpl in the cytoplasm of Dictyostelium', The Journal of Biological Chemistry, 2002, Vol. 277, No. 48, pages 46527-46534 WO 2010/070104 Al Abstract The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.
    [Show full text]
  • Phosphorylation of G Protein-Coupled Receptors: from the Barcode Hypothesis to the Flute Model
    1521-0111/92/3/201–210$25.00 https://doi.org/10.1124/mol.116.107839 MOLECULAR PHARMACOLOGY Mol Pharmacol 92:201–210, September 2017 Copyright ª 2017 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. MINIREVIEW—MOLECULAR PHARMACOLOGY IN CHINA Phosphorylation of G Protein-Coupled Receptors: From the Barcode Hypothesis to the Flute Model Zhao Yang, Fan Yang, Daolai Zhang, Zhixin Liu, Amy Lin, Chuan Liu, Peng Xiao, Xiao Yu, and Jin-Peng Sun Downloaded from Key Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology (Z.Y., Z.L., C.L., P.X., J.-P.S.), Department of Physiology (F.Y., X.Y.), Shandong University School of Medicine, Jinan, Shandong, People’s Republic of China; School of Pharmacy, Binzhou Medical University, Yantai, Shandong, People’s Republic of China (D.Z.); School of Medicine, Duke University, Durham, North Carolina (A.L., J.-P.S.) Received December 10, 2016; accepted February 23, 2017 molpharm.aspetjournals.org ABSTRACT Seven transmembrane G protein-coupled receptors (GPCRs) distinct functional outcomes. Our recent work using unnatural are often phosphorylated at the C terminus and on intracellular amino acid incorporation and fluorine-19 nuclear magnetic loops in response to various extracellular stimuli. Phosphoryla- resonance (19F-NMR) spectroscopy led to the flute model, tion of GPCRs by GPCR kinases and certain other kinases which provides preliminary insight into the receptor phospho- can promote the recruitment of arrestin molecules. The arrestins coding mechanism, by which receptor phosphorylation pat- critically regulate GPCR functions not only by mediating terns are recognized by an array of phosphate-binding pockets receptor desensitization and internalization, but also by redi- on arrestin and are translated into distinct conformations.
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Zheng Zhao, Delft University of Technology Marcel A. van den Broek, Delft University of Technology S. Aljoscha Wahl, Delft University of Technology Wilbert H. Heijne, DSM Biotechnology Center Roel A. Bovenberg, DSM Biotechnology Center Joseph J. Heijnen, Delft University of Technology An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Marco A. van den Berg, DSM Biotechnology Center Peter J.T. Verheijen, Delft University of Technology Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. PchrCyc: Penicillium rubens Wisconsin 54-1255 Cellular Overview Connections between pathways are omitted for legibility. Liang Wu, DSM Biotechnology Center Walter M. van Gulik, Delft University of Technology L-quinate phosphate a sugar a sugar a sugar a sugar multidrug multidrug a dicarboxylate phosphate a proteinogenic 2+ 2+ + met met nicotinate Mg Mg a cation a cation K + L-fucose L-fucose L-quinate L-quinate L-quinate ammonium UDP ammonium ammonium H O pro met amino acid a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar K oxaloacetate L-carnitine L-carnitine L-carnitine 2 phosphate quinic acid brain-specific hypothetical hypothetical hypothetical hypothetical
    [Show full text]
  • Identification of the Enzymatic Pathways of Nucleotide Metabolism in Human Lymphocytes and Leukemia Cells'
    [CANCER RESEARCH 33, 94-103, January 1973] Identification of the Enzymatic Pathways of Nucleotide Metabolism in Human Lymphocytes and Leukemia Cells' E. M. Scholar and P. Calabresi Department of Medicine, The Roger Williams General Hospital, Providence, Rhode Island 02908, and The Division of Biological and Medical Sciences,Brown University, Providence,Rhode Island 02912 SUMMARY monocytes, and lymphocytes, it is difficult to know in what particular fraction an enzyme activity is present. It would therefore be advantageous to separate out the different Extracts of lymphocytes from normal donors and from components of the leukocyte fraction before investigating patients with chronic lymphocytic leukemia (CLL) and acute their enzymatic activities. All previously reported work on the lymphoblastic leukemia were examined for a variety of enzymes of purine nucleotide metabolism was done at best in enzymes with activity for purine nucleotide biosynthesis, the whole white blood cell fraction. Those enzymes found to interconversion, and catabolism as well as for a selected be present included adenine and guanine phosphoribosyltrans number of enzymes involved in pyrimidine nucleotide ferase (2, 32), PNPase2 (7), deoxyadenosine deaminase (7), metabolism. Lymphocytes from all three donor types (normal, ATPase (4), and inosine kinase (21). CLL, acute lymphocytic leukemia) contained the following A detailed knowledge of the enzymatic pathways of purine enzymatic activities: adenine and guanine phosphoribosyl and pyrimidine nucleotide metabolism in normal lymphocytes transferase , adenosine kinase , nucieoside diphosphate kinase, and leukemia cells is important in elucidating any biochemical adenylate kinase, guanylate kinase, cytidylate kinase, uridylate differences that may exist. Such differences may be exploited kinase, adenosine deaminase, purine nucleoside phosphorylase, in chemotherapy and in gaining and understanding of the and adenylate deaminase (with ATP).
    [Show full text]